ARVN:NSD-Arvinas, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 74.03

Change

-8.48 (-10.28)%

Market Cap

USD 3.90B

Volume

0.58M

Average Target Price

USD 106.30 (+43.59%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.

Company Website : http://www.arvinas.com

Address : 5 Science Park, New Haven, CT, United States, 06511

Employees : 133

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.15

52 Week High : 92.77

Short Ratio : 2.74

52 Week Low : 19.68

Shorted Shares : 6,071,948

200 Day Moving Average : 37.71

Shorted Shares Previous Month : 6,644,577

50 Day Moving Average : 73.97

Shares Held By Insiders : 120.37%

Short Percentage : 13.00%

Shares Held by Institutions : 76.78%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.67 (-1.52%)

 USD62.75B 23.65 18.31
REGN Regeneron Pharmaceuticals, Inc

-4.10 (-0.75%)

 USD58.50B 20.09 15.20
MRNA Moderna, Inc

+4.93 (+3.35%)

 USD58.17B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+0.43 (+0.27%)

 USD35.28B 37.44 34.58
BGNE BeiGene, Ltd

-18.57 (-4.93%)

 USD34.32B N/A N/A
SGEN Seagen Inc

-7.48 (-4.15%)

 USD32.24B 68.02 69.56
RPRX Royalty Pharma plc

+1.32 (+2.56%)

 USD32.20B 22.60 11.74
GMAB Genmab A/S

-0.64 (-1.50%)

 USD28.09B 26.59 3.19
BNTX BioNTech SE

-4.32 (-3.91%)

 USD26.63B -99,999.99 N/A
INCY Incyte Corporation

-1.11 (-1.10%)

 USD22.01B 47.64 35.20

ETFs Containing ARVN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.83% 5% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.83% 5% F 3% F
Trailing 12 Months  
Capital Gain 43.44% 58% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.44% 58% F 69% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.24% 76% C 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.24% 76% C 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 66.18% 39% F 18% F
Risk Adjusted Return 66.84% 90% A- 82% B-
Market Capitalization 3.90B 88% B+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.90 69% D+ 89% B+
Price/Book Ratio 19.39 12% F 8% F
Price / Cash Flow Ratio -96.07 94% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.26% 56% F 20% F
Return on Invested Capital -28.04% 77% C+ 26% F
Return on Assets -27.14% 50% F 14% F
Debt to Equity Ratio 0.88% 79% C+ 89% B+
Technical Ratios  
Short Ratio 2.74 52% F 48% F
Short Percent 15.50% 15% F 13% F
Beta 2.15 21% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector